Idorsia IDIA

SWX: IDIA | ISIN: CH0363463438   5/05/2025
1,424 CHF (-4,43%)
(-4,43%)   5/05/2025

2 mei 2025 · Idorsia issues invitation to the 2025 Annual General Meeting of Shareholders · Persbericht

30 april 2025 · Idorsia announces financial results for the first quarter 2025 – QUVIVIQ taking off in Europe and TRYVIO REMS removal increases the value of this outstanding asset · Persbericht

29 april 2025 · New data with daridorexant assessing the transition from night to day in insomnia disorder published in Sleep Medicine · Persbericht

16 april 2025 · Higher cantonal composition authority approved the amendments to the terms of the 2025 convertible bond · Persbericht

9 april 2025 · The effect of aprocitentan for reducing blood pressure and proteinuria in Black patients with resistant hypertension published in Hypertension · Persbericht

9 april 2025 · US FDA approves an updated label for TRYVIO (aprocitentan) removing the REMS requirement · Persbericht

27 maart 2025 · Idorsia publishes its Annual Report 2024 · Persbericht

17 maart 2025 · US FDA removes REMS requirement for TRYVIO (aprocitentan) – minimizing the burden on the healthcare delivery systems and patients · Persbericht

14 maart 2025 · Idorsia announces the publication of positive data with daridorexant in patients with chronic insomnia and nocturia · Persbericht

4 maart 2025 · Idorsia announces financial results for 2024 · Persbericht

27 februari 2025 · Invitation to Idorsia's Full Year 2024 Financial Reporting webcast and conference call · Persbericht

26 februari 2025 · Idorsia reaches an agreement with significant bondholders to restructure its convertible bond debt and to secure funding for future operations · Persbericht

26 februari 2025 · Idorsia and Viatris update their collaboration for selatogrel and cenerimod · Persbericht

26 februari 2025 · Idorsia is released from exclusivity constraint regarding the global rights to aprocitentan – now pivoting to alternative parties · Persbericht

25 februari 2025 · Bondholders approve amended terms of the 2025 convertible bonds · Persbericht

12 februari 2025 · Idorsia publishes the resolutions for the upcoming bondholder meeting · Persbericht

15 januari 2025 · Idorsia presents at J.P. Morgan Healthcare Conference 2025 – fighting to create value for all stakeholders · Persbericht

14 januari 2025 · Idorsia publishes an invitation to a bondholder meeting · Persbericht

13 januari 2025 · Idorsia to call for a bondholder meeting · Persbericht

20 december 2024 · Idorsia provides update on the exclusive negotiations for the global rights to aprocitentan · Persbericht

Mijn selecties